Literature DB >> 12563236

Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases.

Stefan Heinrich1, Henrik Petrowsky, Ingo Schwinnen, Elsbeth Staib-Sebler, Christiane Gog, Ahmed El-Ganainy, Carsten Gutt, Hans-Helge Müller, Matthias Lorenz.   

Abstract

BACKGROUND: Intra-arterial chemotherapy is an effective modality to treat unresectable hepatic metastases from colorectal primaries if systemic chemotherapy has failed. Response rates of more than 40% and a median survival of 15 to 25 months have been reported from randomized trials. In this retrospective study, we analyzed specific technical complications associated with continuous intra-arterial chemotherapy for colorectal liver metastases.
METHODS: From 1982 to 1995, single-center clinical data from 180 patients with colorectal liver metastases were evaluated. Continuous intra-arterial chemotherapy was administered using either an implanted infusion pump or an intra-arterial port with an external infusion pump. The intra-arterial catheter was implanted according to the Watkins' technique. The treatment protocols consisted of 5-fluorouracil- or 5-fluorodeoxyuridine-based regimens.
RESULTS: A total of 70 patients (39%) received an intra-arterial infusion pump and 110 patients (61%) an intra-arterial port. Sixty-eight technical complications affected port systems (62%), whereas 29 patients with pumps (41%) were affected by technical complications. Therapy-relevant complications were observed in 47% of the ports and 30% of the infusion pumps. The median complication-free survival was 12.2 months for infusion pumps and 7.3 months for ports (P =.0016).
CONCLUSIONS: Our data demonstrate that pumps are superior to ports in terms of complication rate and complication-free survival. On the basis of our results, pumps have a potential for a longer treatment, which may result in a prolonged median survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12563236     DOI: 10.1067/msy.2003.37

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  A disappearing hepatic infusion pump.

Authors:  Leonard R Henry; Elin Sigurdson; Cletus A Arciero; James C Watson
Journal:  J Gastrointest Surg       Date:  2005 Jul-Aug       Impact factor: 3.452

2.  Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.

Authors:  Takuya Nakai; Kiyotaka Okuno; Hiroshi Kitaguchi; Hajime Ishikawa; Mitsuo Yamasaki
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

3.  Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: a review of medical devices complications in 3172 patients.

Authors:  Stefano Bacchetti; Enricomaria Pasqual; Elena Crozzolo; Alessandra Pellarin; Pier Paolo Cagol
Journal:  Med Devices (Auckl)       Date:  2009-03-16

Review 4.  Regional therapy of liver metastases.

Authors:  Jonathan Whisenant; Alan Venook
Journal:  Curr Treat Options Oncol       Date:  2004-10

5.  Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach.

Authors:  Bert Hildebrandt; Maciej Pech; Annett Nicolaou; Jan M Langrehr; Jacek Kurcz; Birgit Bartels; Alexandra Miersch; Roland Felix; Peter Neuhaus; Hanno Riess; Bernd Dörken; Jens Ricke
Journal:  BMC Cancer       Date:  2007-04-24       Impact factor: 4.430

6.  Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).

Authors:  Marianne Sinn; Annett Nicolaou; Jens Ricke; Pjotr Podrabsky; Daniel Seehofer; Bernhard Gebauer; Maciej Pech; Peter Neuhaus; Bernd Dörken; Hanno Riess; Bert Hildebrandt
Journal:  BMC Gastroenterol       Date:  2013-08-09       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.